OTCMKTS:MEOBF

Mesoblast Stock Forecast, Price & News

$1.25
0.00 (0.00 %)
(As of 09/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.25
▼
$1.25
50-Day Range
$1.17
▼
$1.50
52-Week Range
$1.12
▼
$4.50
VolumeN/A
Average Volume59,009 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive MEOBF News and Ratings via Email

Sign-up to receive the latest news and ratings for Mesoblast and its competitors with MarketBeat's FREE daily newsletter.


Mesoblast logo

About Mesoblast

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target the cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Itescu Silviu on June 8, 2004 and is headquartered in Melbourne, Australia.

Headlines

Why Mesoblast Stock Is Plunging After Q4 Earnings Report?
Why Mesoblast Stock Is Plunging After Q4 Earnings Report?
August 31, 2021 |  markets.businessinsider.com
Short Interest in Mesoblast Limited (OTCMKTS:MEOBF) Declines By 30.2%
Short Interest in Mesoblast Limited (OTCMKTS:MEOBF) Declines By 30.2%
August 30, 2021 |  americanbankingnews.com
Loss-Making Mesoblast Limited (ASX:MSB) Expected To Breakeven In The Medium-Term
Loss-Making Mesoblast Limited (ASX:MSB) Expected To Breakeven In The Medium-Term
August 24, 2021 |  finance.yahoo.com
Mesoblast Shares 90-Day Survival Outcomes After Remestemcel-L From COVID-19 ARDS Trial
Mesoblast Shares 90-Day Survival Outcomes After Remestemcel-L From COVID-19 ARDS Trial
July 19, 2021 |  finance.yahoo.com
Ninety Day Survival Outcomes in COVID-19 ARDS Trial of Remestemcel-L Presented at ISCT Meeting on Advances in Cell & Gene Therapies for Lung Diseases
Ninety Day Survival Outcomes in COVID-19 ARDS Trial of Remestemcel-L Presented at ISCT Meeting on Advances in Cell & Gene Therapies for Lung Diseases
July 18, 2021 |  benzinga.com
Mesoblast Presents Respiratory Function Results of COVID-19 ARDS Trial at Pulmonary Disease Conference
Mesoblast Presents Respiratory Function Results of COVID-19 ARDS Trial at Pulmonary Disease Conference
July 15, 2021 |  finance.yahoo.com
Mesoblast Updates On Rexlemestrocel-L Program In Chronic Low Back Pain
Mesoblast Updates On Rexlemestrocel-L Program In Chronic Low Back Pain
July 1, 2021 |  finance.yahoo.com
Mesoblast Provides Update on Program for Chronic Low Back Pain Due to Degenerative Disc Disease
Mesoblast Provides Update on Program for Chronic Low Back Pain Due to Degenerative Disc Disease
June 30, 2021 |  finance.yahoo.com
Is Mesoblast (ASX:MSB) Using Debt Sensibly?
Is Mesoblast (ASX:MSB) Using Debt Sensibly?
June 25, 2021 |  finance.yahoo.com
Operational Highlights and Financial Results for the Period Ended March 31, 2021
Operational Highlights and Financial Results for the Period Ended March 31, 2021
June 2, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank™

Overall MarketRank™

0.93 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Mesoblast (OTCMKTS:MEOBF) Frequently Asked Questions

What stocks does MarketBeat like better than Mesoblast?

Wall Street analysts have given Mesoblast a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Mesoblast wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Mesoblast?

Mesoblast saw a drop in short interest during the month of August. As of August 13th, there was short interest totaling 3,824,800 shares, a drop of 30.2% from the July 29th total of 5,482,800 shares. Based on an average daily trading volume, of 100 shares, the days-to-cover ratio is currently 38,248.0 days.
View Mesoblast's Short Interest.

How has Mesoblast's stock been impacted by Coronavirus (COVID-19)?

Mesoblast's stock was trading at $1.45 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MEOBF stock has decreased by 13.8% and is now trading at $1.25.
View which stocks have been most impacted by COVID-19.

Who are Mesoblast's key executives?

Mesoblast's management team includes the following people:
  • Silviu Itescu, Chief Executive Officer, MD & Executive Director
  • Dagmar Rosa-Bjorkeson, Chief Operating Officer
  • Andrew Chaponnel, Chief Financial Officer & Head-Finance
  • Paul Simmons, Head-Research & New Product Development
  • Fred Grossman, Chief Medical Officer

Who are some of Mesoblast's key competitors?

Some companies that are related to Mesoblast include (TNGN) (TNGN), 3SBio (TRSBF), 45525 (CUR.TO) (CUR), Abattis Bioceuticals (ATTBF), Abzena (ABZA), Acrux (ACR), Actinogen Medical (ACW), AdAlta (1AD), Admedus (AHZ), Algernon Pharmaceuticals (AGNPF), Almirall (LBTSF), Amarantus BioScience (AMBS), Amplia Therapeutics (ATX), Anatara Lifesciences (ANR) and Annovis Bio (ANVS).
View all of MEOBF's competitors.

What is Mesoblast's stock symbol?

Mesoblast trades on the OTCMKTS under the ticker symbol "MEOBF."

How do I buy shares of Mesoblast?

Shares of MEOBF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mesoblast's stock price today?

One share of MEOBF stock can currently be purchased for approximately $1.25.

How many employees does Mesoblast have?

Mesoblast employs 102 workers across the globe.

What is Mesoblast's official website?

The official website for Mesoblast is www.mesoblast.com.

Where are Mesoblast's headquarters?

Mesoblast is headquartered at 55 Collins Street, Melbourne, Victoria (VIC).

How can I contact Mesoblast?

Mesoblast's mailing address is 55 Collins Street, Melbourne, Victoria (VIC). The company can be reached via phone at (139) 639-6036.


This page was last updated on 9/16/2021 by MarketBeat.com Staff

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.